Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
- Oral presentation of intravenous VRDN-001 preclinical and Phase 1/2 clinical data –
- Poster presentations of subcutaneous VRDN-003 preclinical data –
- Subcutaneous program selection for.
Viridian Therapeutics, Inc : Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
- Oral presentation to describe distinct receptor binding and mechanistic characteristics of VRDN-001, Company’s lead pipeline candidate in its thyroid eye disease program -
- Poster. | June 13, 2023